Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients.
Miglietta F, Pontolillo L, De Angelis C, Caputo R, Marino M, Bria E, Di Rienzo R, Verrazzo A, Buonerba C, Tortora G, Di Lorenzo G, Del Mastro L, Giuliano M, Montemurro F, Puglisi F, Guarneri V, De Laurentiis M, Scafuri L, Arpino G. Miglietta F, et al. Among authors: del mastro l. Breast. 2024 Jun;75:103713. doi: 10.1016/j.breast.2024.103713. Epub 2024 Mar 9. Breast. 2024. PMID: 38493590 Free PMC article. Review.
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, Del Mastro L, Lauria R, Marinelli A, Gallo C. Bianco AR, et al. Among authors: del mastro l. Ann N Y Acad Sci. 1993 Nov 30;698:330-8. doi: 10.1111/j.1749-6632.1993.tb17223.x. Ann N Y Acad Sci. 1993. PMID: 8279772 Clinical Trial. No abstract available.
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, Del Mastro L. Venturini M, et al. Among authors: del mastro l. Breast Cancer Res Treat. 2006 Jan;95(1):45-53. doi: 10.1007/s10549-005-9030-x. Breast Cancer Res Treat. 2006. PMID: 16267615 Clinical Trial.
Aromatase inhibitors as adjuvant therapy for breast cancer.
Montemurro F, Aglietta M, Del Mastro L. Montemurro F, et al. Among authors: del mastro l. J Clin Oncol. 2009 May 20;27(15):2566-7. doi: 10.1200/JCO.2009.22.2695. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332706 No abstract available.
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
Venturini M, Bighin C, Puglisi F, Olmeo N, Aitini E, Colucci G, Garrone O, Paccagnella A, Marini G, Crinò L, Mansutti M, Baconnet B, Barbato A, Del Mastro L. Venturini M, et al. Among authors: del mastro l. Breast. 2010 Oct;19(5):333-8. doi: 10.1016/j.breast.2010.01.018. Epub 2010 Feb 24. Breast. 2010. PMID: 20185313 Free article. Clinical Trial.
Follow-up of patients with early breast cancer: is it time to rewrite the story?
Puglisi F, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F, Gori S, Del Mastro L. Puglisi F, et al. Among authors: del mastro l. Crit Rev Oncol Hematol. 2014 Aug;91(2):130-41. doi: 10.1016/j.critrevonc.2014.03.001. Epub 2014 Mar 22. Crit Rev Oncol Hematol. 2014. PMID: 24726438 Free article. Review.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Del Mastro L, et al. Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2. Lancet. 2015. PMID: 25740286 Clinical Trial.
Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L. Lambertini M, et al. Among authors: del mastro l. Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22. Oncologist. 2015. PMID: 26099741 Free PMC article.
327 results